Javascript must be enabled to continue!
Pitfalls due to improper positioning of Impella®CP device for left ventricular support: a case series
View through CrossRef
Background: The Impella® device is a type of antegrade left ventricular assist device that includes a pump catheter designed to reside in the mid-left ventricular cavity. It has received approval for temporary use in providing left ventricular support, with the aim of augmenting cardiac output and reducing myocardial oxygen demand. We document four cases in which we encountered challenges in circulatory management during Impella device insertion. These challenges arose from issues such as incorrect positioning leading to restricted maximum flow rate or the development of new-onset aortic insufficiency (AI) associated with the placement of the device.
Cases presentation: Two of our four patients showed improper positioning; either the inlet part was too much in the ventricle or too close to the heart wall. Due to the placement of the Impella, all four patients experienced the development of new-onset aortic insufficiency with a relatively low total assisted flow rate. In one of the cases, sufficient total flow was achieved when the Impella device was utilized alongside veno-arterial extracorporeal membrane oxygenation (ECMO).
Conclusion: Circulatory management with Impella device insertion can be challenging due to certain pitfalls, such as the incorrect positioning of Impella and the development of AI following Impella placement with a restricted flow rate. During the acute phase when patients experience deteriorating cardiogenic shock, the use of ECMO for management is considered to be an effective approach.
Abbreviations: ECMO: Extra-corporeal membranous oxygenation; PCPS: Percutaneous cardiopulmonary support; LVAD: Left ventricular assist device; LVEF: Left ventricular ejection fraction; CCO: Continuous cardiac output; AI: Aortic insufficiency.
Keywords: Aortic Insufficiency; ECMO; Cardiogenic Shock; Impella; Ventricular Assist Device
Citation: Abdalwahab A, Ismail AA, Hammad YM. Pitfalls due to improper positioning of Impella®CP device for left ventricular support: a case series. Anaesth. pain intensive care 2024;28(5):119-123.
DOI: 10.35975/apic.v29i1.2656
Received: November 24, 2024; Reviewed: December 30, 2024; Accepted: December 30, 2024
Aga Khan University Hospital
Title: Pitfalls due to improper positioning of Impella®CP device for left ventricular support: a case series
Description:
Background: The Impella® device is a type of antegrade left ventricular assist device that includes a pump catheter designed to reside in the mid-left ventricular cavity.
It has received approval for temporary use in providing left ventricular support, with the aim of augmenting cardiac output and reducing myocardial oxygen demand.
We document four cases in which we encountered challenges in circulatory management during Impella device insertion.
These challenges arose from issues such as incorrect positioning leading to restricted maximum flow rate or the development of new-onset aortic insufficiency (AI) associated with the placement of the device.
Cases presentation: Two of our four patients showed improper positioning; either the inlet part was too much in the ventricle or too close to the heart wall.
Due to the placement of the Impella, all four patients experienced the development of new-onset aortic insufficiency with a relatively low total assisted flow rate.
In one of the cases, sufficient total flow was achieved when the Impella device was utilized alongside veno-arterial extracorporeal membrane oxygenation (ECMO).
Conclusion: Circulatory management with Impella device insertion can be challenging due to certain pitfalls, such as the incorrect positioning of Impella and the development of AI following Impella placement with a restricted flow rate.
During the acute phase when patients experience deteriorating cardiogenic shock, the use of ECMO for management is considered to be an effective approach.
Abbreviations: ECMO: Extra-corporeal membranous oxygenation; PCPS: Percutaneous cardiopulmonary support; LVAD: Left ventricular assist device; LVEF: Left ventricular ejection fraction; CCO: Continuous cardiac output; AI: Aortic insufficiency.
Keywords: Aortic Insufficiency; ECMO; Cardiogenic Shock; Impella; Ventricular Assist Device
Citation: Abdalwahab A, Ismail AA, Hammad YM.
Pitfalls due to improper positioning of Impella®CP device for left ventricular support: a case series.
Anaesth.
pain intensive care 2024;28(5):119-123.
DOI: 10.
35975/apic.
v29i1.
2656
Received: November 24, 2024; Reviewed: December 30, 2024; Accepted: December 30, 2024.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Clinical outcomes of Impella support for cardiogenic shock and high-risk percutaneous coronary intervention
Clinical outcomes of Impella support for cardiogenic shock and high-risk percutaneous coronary intervention
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Hemodynamic improvement with Impella RP in acute massive pulmonary embolism: a narrative review of cardiovascular outcomes and pulmonary catheter pressure assessment
Hemodynamic improvement with Impella RP in acute massive pulmonary embolism: a narrative review of cardiovascular outcomes and pulmonary catheter pressure assessment
Background:
Acute massive pulmonary embolism (PE) can lead to right ventricular (RV) failure and cardiogenic shock, requiring urgent treatment. Thrombolytic therapy is ...
Impella RP for Patients with Acute Right Ventricular Failure and Cardiogenic Shock: A Subanalysis from the IMP-IT Registry
Impella RP for Patients with Acute Right Ventricular Failure and Cardiogenic Shock: A Subanalysis from the IMP-IT Registry
The use of percutaneous right ventricular assist devices (pRVADs) to support patients with right ventricular (RV)-predominant cardiogenic shock (CS) refractory to optimal medical t...

